Please login to the form below
Inebilizumab
This page shows the latest Inebilizumab news and features for those working in and with pharma, biotech and healthcare.
Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition
Currently, Viela has one US Food and Drug Administration (FDA) approved asset – Uplizna (inebilizumab-cdon), which is indicated for the treatment of the rare condition neuromyelitis optica spectrum disorder (NMOSD).
Latest news
-
US, EU regulators start review of Roche’s Soliris rival satralizumab
Meanwhile, another emerging rival in the NMOSD category is Viela Bio, whose inebilizumab was filed for approval with the FDA earlier this year. ... Viela thinks inebilizumab has a dosing advantage over both Soliris and satralizumab as it can be
-
Roche presents new data in NMOSD, could challenge Alexion's Soliris
Another contender comes from Viela Bio, inebilizumab, which was filed for approval with the FDA earlier this month. ... Viela thinks inebilizumab has a dosing advantage over both these rivals as it can be delivered just twice a year.
-
Medimmune-born Viela files $150m IPO, eyes first product launch
The money raised in the IPO will give the Maryland-based biotech the financial muscle it needs to start building the commercial platform for its lead drug inebilizumab, which has just ... Inebilizumab is an anti-CD19 antibody developed initially to treat
US, EU regulators start review of Roche’s Soliris rival satralizumab
Medimmune-born Viela files $150m IPO, eyes first product launch
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Events Executive
-
Depending on Experience
-
Digital project manager
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Live Webinar: Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- This month in 1939: How dead cattle led to the discovery of warfarin
- Recruiting patients for real-world studies – the power of a digital campaign
PMHub
Streaming Well
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
